Amneal Pharmaceuticals, Inc. Class A AMRX

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 12.5% in the afternoon session after the company announced that the U.S. Food and Drug Administration approved its generic lanreotide injection for immediate launch.

- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE® Depot and will launch imme

What a time it’s been for Amneal. In the past six months alone, the company’s stock price has increased by a massive 47.7%, reaching $18.31 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

In early September 2026, Amneal Pharmaceuticals filed a shelf registration for up to US$522.69 million of Class A common shares, covering 28,942,098 securities, shortly after reporting a very strong second-quarter performance with revenue of US$796.2 million and an increase of 9.9% year on year. The combination of an impressive earnings beat, raised full-year EPS guidance, and a large new shelf registration raised questions about how Amneal might balance growth investments with the potential...

On August 10, Amneal Pharmaceuticals (NASDAQ:AMRX) completed its acquisition of Kashiv BioSciences, a deal that co-CEO Chirag Patel called a pivotal step in the company’s push to become America’s top Affordable Medicines company. The combination pairs Kashiv’s biologics research and manufacturing with Amneal’s commercial reach, giving Amneal a rare end-to-end presence in biosimilars. It is […]

Amneal Pharmaceuticals is back in focus after analysts lifted fair value from US$20.25 to US$21.00 per share, reflecting updated assumptions in recent models. Much of this shift lines up with Street research that leans positive on growth, execution, and the potential from new product launches and a broader portfolio. Keep reading to see what is changing in the narrative around Amneal Pharmaceuticals and how you can track those moving parts over time. Stay updated as the Fair Value for Amneal...

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.